Legend Biotech logo
Legend Biotech
LEGN | NASDAQ
Chart Builder DCF Calculator
$15.99
-$1.51 (-8.63%)
At close: Nov 16, 2026, 4:00 PM ET
$16.10
+$0.11 (+0.69%)
After-hours: Nov 16, 2026, 7:52 PM ET

Legend Biotech Company Profile

Company profile explained

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Key Executives

Name Position
Ingrid Zhang Chief Executive Officer
Carlos Santos Chief Financial Officer
Alan Bash President of CARVYKTI Business Unit
Ananda Elizabeth Martin Global Compliance Officer
Birk Vanderweeen Senior Vice President of Global Manufacturing & Supply
Joanne Choi Senior Manager of Investor Relations
Robert Staloff General Counsel
Surabhi Verma Manager of Investor Relations & Corporate Communications
Ying Huang Advisor
Yuhong Qiu Interim Head of Research & Development and Senior VP of Regulatory Affairs

Latest SEC Filings

Date Type Title
Oct 15, 2026 6-K Filing
Oct 13, 2026 6-K Filing
Oct 07, 2026 S-8 Filing
Oct 01, 2026 4 Filing
Sep 28, 2026 4 Filing
Sep 28, 2026 4 Filing
Sep 28, 2026 4 Filing
Sep 28, 2026 4 Filing
Sep 28, 2026 4 Filing
Sep 28, 2026 4 Filing
View All SEC Filings ➞
Legend Biotech
Legend Biotech logo
Country United States
IPO Date Jun 5, 2020
Industry Biotechnology
Sector Healthcare
Employees 3,200
CEO Alan S. Bash

Contact Details

2101 Cottontail Lane Somerset, New Jersey 08873 United States

Stock Details

Ticker Symbol LEGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001801198
CUSIP Number 52490G102
ISIN Number US52490G1022
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.